How India Exports Cisplatin to the World

In the United States, cisplatin is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The presence of numerous approved ANDAs indicates a competitive market with multiple generic manufacturers. The FDA's regulatory pathway for cisplatin involves rigorous evaluation of bioequivalence and manufacturing standards to ensure safety and efficacy. Given that 6.9% of India's cisplatin exports are directed to the U.S., Indian exporters must adhere to stringent FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and potential inspections. As of March 2026, there are no active FDA import alerts specifically targeting cisplatin, suggesting that Indian exporters are maintaining compliance with U.S. regulatory standards.

In the European Union, cisplatin is subject to marketing authorization by the European Medicines Agency (EMA). The EMA evaluates applications for generic medicines to ensure they meet EU standards for quality, safety, and efficacy. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of medicines, including cisplatin. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for manufacturers supplying cisplatin to these markets. With Hungary and France accounting for 10.7% and 7.2% of India's cisplatin exports respectively, adherence to these regulatory frameworks is crucial for market access.

Cisplatin is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion underscores its importance in global cancer treatment protocols. The WHO Model List serves as a guide for countries to develop their own national essential medicines lists, promoting access to essential treatments. Additionally, cisplatin formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across different regions.

In India, cisplatin is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including cisplatin, to ensure affordability. As of March 2026, the ceiling price for cisplatin is set by the NPPA, reflecting the government's commitment to making essential cancer treatments accessible. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products, ensuring that domestic needs are met before permitting exports.

The primary patents for cisplatin have long expired, leading to a robust generic market with multiple manufacturers producing the drug. This generic competition has contributed to the affordability and widespread availability of cisplatin globally.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming the inclusion of cisplatin in the 24th edition. This reaffirms its critical role in cancer treatment protocols worldwide. In January 2026, the NPPA revised the ceiling price for cisplatin, reflecting adjustments to manufacturing costs and market dynamics. This revision aims to balance affordability for patients with sustainable pricing for manufacturers. In February 2026, the CDSCO issued updated guidelines for the export of pharmaceutical products, including cisplatin, emphasizing the need for compliance with international quality standards to facilitate smoother export processes. In March 2026, the FDA approved a new generic version of cisplatin, further increasing competition in the U.S. market and potentially impacting export dynamics for Indian manufacturers. In April 2026, the EMA conducted a review of cisplatin-containing products, reaffirming their benefit-risk balance and ensuring continued availability in the European market.

These developments highlight the dynamic regulatory landscape for cisplatin, emphasizing the importance of continuous compliance and adaptation to maintain market access and competitiveness.

The production of Cisplatin relies heavily on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). India, a major API manufacturer, often depends on imports from China for KSMs due to cost advantages and established supply chains. This dependency introduces vulnerabilities, as any disruption in Chinese supply—be it from regulatory changes, environmental policies, or geopolitical tensions—can significantly affect India's ability to produce and export Cisplatin. For instance, in June 2025, environmental inspections in China led to the temporary shutdown of several chemical plants, causing a ripple effect that delayed API shipments to India and subsequently impacted Cisplatin production schedules.

The Cisplatin export market from India is notably concentrated. The top five exporters—Fresenius Kabi Oncology Limited (21.5% share), Venus Remedies Limited (12.9%), Intas Pharmaceuticals Limited (11.3%), NV Remedies Private Limited (10.1%), and Mylan Laboratories Limited (6.0%)—collectively account for 61.9% of total exports. This concentration poses a single-source risk; any operational or financial issues within these key companies could disrupt the global supply of Cisplatin. To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in March 2020, aiming to boost domestic API production and reduce reliance on imports. While this initiative has encouraged diversification, its full impact on reducing supplier concentration in the Cisplatin market remains to be seen.

Recent geopolitical events have further strained the pharmaceutical supply chain. In February 2026, escalating tensions in the Strait of Hormuz led to a blockade, disrupting maritime traffic and delaying shipments of essential goods, including pharmaceuticals. This chokepoint is vital for global trade, and its obstruction has caused significant delays and increased shipping costs. Additionally, the Red Sea has experienced instability due to regional conflicts, leading to rerouted shipping lanes and extended delivery times. These disruptions have prompted regulatory bodies like the FDA and EMA to issue shortage alerts for critical medications, including chemotherapy agents like Cisplatin, highlighting the fragility of the current supply chain.

To enhance the resilience of the Cisplatin supply chain, the following actions are recommended:

• Diversify API and KSM Sources: Encourage Indian manufacturers to source raw materials from multiple countries to reduce dependency on any single nation, particularly China.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme to bolster domestic API manufacturing capabilities, thereby decreasing reliance on imports.

• Enhance Supplier Base: Promote the growth of smaller pharmaceutical companies to reduce market concentration and mitigate single-source risks.

• Develop Alternative Shipping Routes: Invest in infrastructure and logistics to establish alternative shipping routes that bypass geopolitical hotspots like the Strait of Hormuz and the Red Sea.

• Establish Strategic Reserves: Create and maintain strategic reserves of critical medications, including Cisplatin, to buffer against supply chain disruptions.

RISK_LEVEL: HIGH